Carmen Moreno-Aguilar

Dr. Carmen Moreno-Aguilar


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2022 in Toxins
Verified
Journal Article
Open access
PDF file
Berta Ruiz-LeónBerta Ruiz-León
Berta Ruiz-León
PSPilar Serrano
Pilar Serrano
CVCarmen Vidal
Carmen Vidal
Carmen Moreno-AguilarCarmen Moreno-Aguilar
Carmen Moreno-Aguilar
Wasp allergy with a diagnostic profile of double sensitizations to vespid venom is a frequent clinical problem in areas where different genera of wasps are present. Identification of the insect responsible for serious reactions poses a diagnostic challenge as the only effective treatment to date is immunotherapy based on the specific venom. In southern Europe, the double sensitization to Vespula and Polistes venoms is highly frequent. It has been shown that the major allergenic proteins (Phospholipase A1 and Antigen 5) share sequences across the different genera and species, which would be the cause of cross-reactivity. Additionally, the minor allergens (Dipeptidyl-peptidases, Vitellogenins) have been found to share partial sequence identity. Furthermore, venom contains other homologous proteins whose allergenic nature still remains to be clarified. The traditional diagnostic tools available are insufficient to discriminate between allergy to Vespula and Polistes in a high number of cases. IgE inhibition is the technique that best identifies the cross-reactivity. When a double sensitization has indeed been shown to exist or great uncertainty surrounds the primary sensitization, therapy with two venoms is advisable to guarantee the safety of the patient. In this case, a strategy involving alternate administration that combines effectiveness with efficiency is possible.

1 January 2015 in Clinical and Translational Allergy
Verified
Journal Article
Open access
PDF file
Carmen Moreno-AguilarCarmen Moreno-Aguilar
Carmen Moreno-Aguilar
BPBlanca Sáenz De San Pedro
Blanca Sáenz De San Pedro
CMCarmen Millán
Carmen Millán
CPCarmen Panizo
Carmen Panizo
SMSantiago Martín
Santiago Martín
FFFernando Florido
Fernando Florido
Background: A new subcutaneous specific immunotherapy (SCIT) product adsorbed on aluminium hydroxide has been developed with a short and simplified up‐dosing phase, containing a biologically standardized allergen pollen extract from Olea europaea.Objective: To assess the tolerability profile of the updosing phase and its immunological effect, in terms of specific IgG4 and IgE levels and immediate skin reactivity.Material and methods: The study was an exploratory, multi‐centre, open‐label, single‐arm, phase II/III clinical trial. Adults with a clinical history of allergic rhinoconjunctivitis with/without asthma due to sensitization to olive pollen were selected. Five up‐dosing doses (300, 600, 3000, 6000 and 15000SQ+) were administered at weekly intervals, followed by a maintenance dose (15000SQ+) after 2 weeks. Adverse events were collected during the 30 min observation period after injections, after a telephone contact 2 days after each visit, and after reviewing the subjects’ diary. IgG4 and IgE levels and immediate skin reactivity were evaluated at the beginning and at the end of the trial.Results: Ninety‐three subjects were included in the trial (mean age, 35.7 ± 10.3 years; women, 66.7 %). A total of 95 adverse drug reactions, all mild in intensity and non‐serious, were reported during the trial: 85 local in 34.4 % subjects, 9 systemic in 4.3 % subjects and one non‐specific (grade 0). Within 6 weeks, significant changes in IgG4 and IgE levels and in immediate skin reactivity to Olea europaea were accomplished.Conclusion: This new SCIT derived from pollen of Olea europaea presented a good tolerability profile and induced significant immunological responses already after a 6 week treatment. However, the non‐controlled design may limit the interpretation of these results.Trial registration: EudraCT no: 2011‐004852‐20; ClinicalTrials.gov Identifier: NCT01674595.

22 June 2022 in Toxins
Verified
Journal Article
Open access
PDF file
ANAna Navas
Ana Navas
Berta Ruiz-LeónBerta Ruiz-León
Berta Ruiz-León
PSPilar Serrano
Pilar Serrano
MAManuel Martí Antonio
Manuel Martí Antonio
MEM Luisa Espinazo
M Luisa Espinazo
Carmen Moreno-AguilarCarmen Moreno-Aguilar
Carmen Moreno-Aguilar
Inducing tolerance in Hymenoptera-allergic patients, bee venom immunotherapy (BVIT) is a widely accepted method to treat severe allergy to bee stings. In order to increase the existing knowledge on the underlying immunological mechanisms and look for possible biomarkers predictive of efficacy, a group of 20 bee-venom-allergic patients (AG) were thoroughly examined during their first year of BVIT. In addition, the results of treated patients with those of an untreated group of 20 tolerant beekeepers (TG) who had previously shown a firm suppressor-regulatory profile were compared. Tolerance in AG patients was invariably associated with a significant regulatory response characterised by the expansion of Helios− subpopulation and increased IL-10, specific IgG4 (sIgG4), and kynurenine levels. Although specific IgE (sIgE) levels increased transiently, surprisingly, the T helper type 2 (Th2) population and IL-4 levels rose significantly after one year of immunotherapy. Thus, the picture of two parallel phenomena emerges: a tolerogenic response and an allergenic one. Comparing these results with those obtained from the TG, different immunological mechanisms appear to govern natural and acquired tolerance to immunotherapy. Of particular interest, the kynurenine levels and T regulatory (Treg) Helios− population could be proposed as new biomarkers of response to BVIT.

25 July 2022 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
MRMarisa Espinazo Romeu
Marisa Espinazo Romeu
ACAntonio Letrán Camacho
Antonio Letrán Camacho
Carmen Moreno-AguilarCarmen Moreno-Aguilar
Carmen Moreno-Aguilar
ARAurora Jurado Roger
Aurora Jurado Roger
FBFrancisco Moreno Benítez
Francisco Moreno Benítez

1 January 2011
Verified
Journal Article
Closed access
Carmen Moreno-AguilarCarmen Moreno-Aguilar
Carmen Moreno-Aguilar
MBM J Barasona
M J Barasona
PSP Serrano
P Serrano
JJJ L Justicia
J L Justicia
JRJ M Ruz
J M Ruz
FGF Guerra
F Guerra